Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I–III trials

The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants

(2015) Anthony Ajua et al.   MALARIA JOURNAL

A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine

(2014) Michael T White et al.   BMC Medicine

Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01E in Young Children

(2014) Ally Olotu et al.   PLoS One

Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines

(2014) Geert Leroux-Roels et al.   Human Vaccines & Immunotherapeutics

Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites

(2014)   PLOS MEDICINE

Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data

(2013) George M Warimwe et al.   BMC Medicine

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data

(2013) Philip Bejon et al.   LANCET INFECTIOUS DISEASES

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region

(2013) Salim Abdulla et al.   MALARIA JOURNAL

Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria Exposure

(2013) Ally Olotu et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against Plasmodium falciparum Infection

(2013) Michael T. White et al.   PLoS One

Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine

(2012) A. Horowitz et al.   JOURNAL OF IMMUNOLOGY

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E

(2012) Francis M. Ndungu et al.   PLoS One

Unexpected fold in the circumsporozoite protein target of malaria vaccines

(2012) M. B. Doud et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials

(2011) Johan Vekemans et al.   Human vaccines & immunotherapeutics

Safety and efficacy of the RTS,S/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial

(2011) Kwaku Poku Asante et al.   LANCET INFECTIOUS DISEASES

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial

(2011) Ally Olotu et al.   LANCET INFECTIOUS DISEASES

First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Induction of Plasmodium falciparum-Specific CD4+ T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01E and RTS,S/AS02D

(2011) Selidji T. Agnandji et al.   PLoS One

T Cell Responses to the RTS,S/AS01E and RTS,S/AS02D Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children

(2011) Daniel Ansong et al.   PLoS One

Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells

(2011) Joanne M. Lumsden et al.   PLoS One

Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria

(2011) Ally Olotu et al.   PLoS One

Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trial

(2011) Pedro Aide et al.   VACCINE

Five year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia

(2010) Kalifa Bojang et al.   Human vaccines & immunotherapeutics

From the circumsporozoite protein to the RTS,S/AS candidate vaccine

(2010) Joe Cohen et al.   Human vaccines & immunotherapeutics

Vaccine Adjuvants: Putting Innate Immunity to Work

(2010) Robert L. Coffman et al.   IMMUNITY

Further Analysis of Correlates of Protection from a Phase 2a Trial of the Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults

(2010) Ally Ibrahim Olotu et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of the Safety and Immunogenicity of the RTS,S/AS01EMalaria Candidate Vaccine When Integrated in the Expanded Program of Immunization

(2010) Selidji T. Agnandji et al.   JOURNAL OF INFECTIOUS DISEASES

Expression of Genes Associated with Immunoproteasome Processing of Major Histocompatibility Complex Peptides Is Indicative of Protection with Adjuvanted RTS,S Malaria Vaccine

(2010) Maryanne T. Vahey et al.   JOURNAL OF INFECTIOUS DISEASES

Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial

(2010) Pedro Aide et al.   PLoS One

Plasmodium falciparum-Specific Cellular Immune Responses after Immunization with the RTS,S/AS02D Candidate Malaria Vaccine in Infants Living in an Area of High Endemicity in Mozambique

(2009) A. Barbosa et al.   INFECTION AND IMMUNITY

Long‐Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican Children

(2009) Jahit Sacarlal et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

(2009) Kent E. Kester et al.   JOURNAL OF INFECTIOUS DISEASES

Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children

(2009) Caterina Guinovart et al.   PLoS One

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area

(2009) Mark E. Polhemus et al.   PLoS One

Impact of RTS,S/AS02A and RTS,S/AS01B on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine Clinical Trial

(2009) John N. Waitumbi et al.   PLoS One

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon

(2009) Bertrand Lell et al.   PLoS One

Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children

(2009) Seth Owusu-Agyei et al.   PLoS One

Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age

(2008) Philip Bejon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants

(2008) Salim Abdulla et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

(2008) Kent E. Kester et al.   VACCINE